Actualités sur Health

25.05.2016 – 01:52
Resverlogix Corp.
Resverlogix Presents New Complement Data and Establishes Renal Clinical Advisory Board at the 53rd Annual European Renal Association - European Dialysis & Transplant Association Congress (ERA-EDTA)
Calgary, Alberta (ots/PRNewswire) - "Apabetalone, a selective bromodomain extra-terminal (BET) protein inhibitor that significantly decreases abundance and activity of complement proteins" Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announces that new data was presented at the ERA-EDTA Congress in ...
plus
24.05.2016 – 14:03
Isofol Medical AB
Isofol Announces Successful Meetings With European and US Regulatory Authorities Regarding the Design of a Pivotal Phase II Clinical Trial of Isofol's Lead Drug Candidate, Modufolin®
Gothenburg, Sweden (ots/PRNewswire) - Isofol Medical AB, a clinical stage pharmaceutical company, developing novel products for unmet needs within oncology is pleased with the outcome of these meetings and will initiate preparations for a pivotal Phase II/III clinical trial in colorectal cancer. This presents the ...
plus
24.05.2016 – 08:31
JTI Japan Tobacco International AG
WHO Censorship Tactics Should be Exposed at World Health Assembly
Geneva (ots/PRNewswire) - As the Annual Summit Takes Place This Week, Global Leaders Have an Opportunity to Scrutinize WHO's definition of transparency and accountability Health Ministers from 194 countries will gather this week in Geneva to set the direction for future health policy around the world. JTI - Japan Tobacco International - is calling for the Assembly to urgently address an alarming transparency and ...
plus
18.05.2016 – 23:16
Merck Healthcare Germany
Bringing Innovation to Patients: Merck Presents New Advances at ASCO 2016
Darmstadt, Germany (ots/PRNewswire) - Not intended for UK- or US-based media ASCO Abstract # Avelumab: 4009, TPS4134, TPS4135, 9036, TPS9105, 3055, TPS3106, 8503, 4514, 4516, 5533, TPS5600, TPS4580, 9508; tepotinib: 4072 - Abstracts featuring Merck compounds span a broad range of cancers, with an emphasis on those which are difficult-to-treat and represent ...
plus
04.05.2016 – 18:38
Teva Pharmaceuticals Europe BV
Teva Breathes Its Way to a Guinness World Records Title
Amsterdam (ots/PRNewswire) - What can you do in 30 minutes? Catch up on your favourite sitcom? Burn 180 calories on an exercise bike? Clean the bathroom? Or break a Guinness World Records(TM) title? (Logo: http://photos.prnewswire.com/prnh/20160504/363641LOGO ) (Photo: http://photos.prnewswire.com/prnh/20160504/363642 ) That is what over 600 employees from Teva have done. Taking a break from their day jobs in areas such ...
plus
28.04.2016 – 09:01
Accuray Europe
Accuray to Unveil Latest Innovations at Estro
Sunnyvale, California (ots/PRNewswire) - Next generation delivery system designed for increased throughput, higher reliability and ease of serviceability Accuray Incorporated (NASDAQ: ARAY) announced the company will showcase its portfolio of radiation therapy delivery systems and software solutions at the annual European Society for Therapeutic Radiology and Oncology (ESTRO) meeting being held in Turin, Italy April 29 - ...
plus

25.04.2016 – 08:13
Merck Healthcare Germany
Phase III TAILOR Landmark Study Demonstrates Significant Benefits of Erbitux in Combination with FOLFOX Over FOLFOX Alone
Darmstadt, Germany (ots/PRNewswire) - Not intended for UK- or US-based media - Chinese pivotal Phase III study meets its primary endpoint of increased progression-free survival in first-line treatment of patients with RAS wild-type metastatic colorectal cancer - Merck will work with relevant authorities to make ...
plus
20.04.2016 – 22:48
Montrusco Bolton Investments Inc.
Montrusco Bolton Investments Not Supporting Concordia Healthcare Corp Compensation Committee
Montreal (ots/PRNewswire) - Montrusco Bolton Investments (MBI) has reviewed the 2015 compensation of Concordia Healthcare Corp's executive team. Based on an ISS report and our in-house assessment, we are of the view that the total compensation of senior executives is exorbitant. MBI agrees with ISS that the lack of transparency regarding how compensation is determined, ...
plus
19.04.2016 – 17:01
EBOVAC1
Global Public-Private Partnership Announces Publication of Positive Phase 1 Data for Ebola Vaccine Regimen in JAMA
London (ots/PRNewswire) - First published clinical data show prime-boost Ebola vaccine regimen produced an antibody response in 100 percent of healthy volunteers that was sustained 8 months following immunization An Ebola vaccine is still urgently needed to address the problem of Ebola persistence in affected ...
plus
18.04.2016 – 16:20
Shire Pharmaceuticals Group Plc
Shire plc ("Shire") Publication of Circular, Notice of General Meeting and Prospectus and Directorate Change
Dublin (ots/PRNewswire) - NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF THAT JURISDICTION. PLEASE SEE THE IMPORTANT NOTICE WITHIN THIS ANNOUNCEMENT. Publication of Circular, Notice and Prospectus ...
plus
17.04.2016 – 08:01
Novo Nordisk
Novo Nordisk mark World Haemophilia Day and unveil the 2016 HERO Research Grant
Zürich, Switzerland (ots/PRNewswire) - This material is intended for global medical media only. For journalistic assessment and preparation before publication. Today, on World Haemophilia Day, Novo Nordisk announces that the grant scheme to support and encourage research projects focused on the psychosocial issues faced by people with haemophilia is open for ...
plus
15.04.2016 – 09:01
Debiopharm International SA
Debiopharm International SA Announces Presentation at AACR of Non-clinical Data Relating to its Targeted Investigational Compound Debio 1347/CH5183284, a Selective FGFR 1,2,3 Inhibitor
Lausanne, Switzerland (ots/PRNewswire) - Debiopharm International SA (Debiopharm), a Swiss-based company, part of Debiopharm Group(TM), today announces that non-clinical data on the clinical-stage investigational compound Debio 1347/CH5183284 (FGFR 1,2,3 inhibitor) will be presented at the 2016 Annual Meeting of the ...
plus

13.04.2016 – 17:39
Qiagen N.V.
QIAGEN Posts 2015 Annual Report on Its Website
Venlo, The Netherlands (ots/PRNewswire) - QIAGEN N.V. (Nasdaq:QGEN) (Frankfurt:QIA) has posted its 2015 Annual Report on its website at http://www.qiagen.com/About-Us/Investors/Financial-Information/Financial-Reports QIAGEN's Annual Report on Form 20-F for the year ended December 31, 2015 has been filed with the U.S. Securities and Exchange Commission (SEC) on February 26, 2016, a copy of which can be found on the website ...
plus
12.04.2016 – 08:01
Echosens
FibroScan® New Generation Extends Access to Non-invasive Liver Diagnosis
Paris (ots/PRNewswire) - Echosens (http://www.echosens.com/en/) extends its product range with the launch of a new FibroScan® product, the reference liver diagnosis equipment, at EASL 2016 in Barcelona: FibroScan® 530 Compact. (Logo: http://photos.prnewswire.com/prnh/20160411/353647LOGO ) (Photo: http://photos.prnewswire.com/prnh/20160411/353648 ) The FibroScan® 530 ...
plus
11.04.2016 – 12:31
Astellas Pharma EMEA
International Consensus Report Highlights Need for Improved Management of Clostridium difficile Infection (CDI) in Inflammatory Bowel Disease (IBD) Patients
Amsterdam, The Netherlands (ots/PRNewswire) - In patients with IBD, CDI is a key risk factor for both morbidity and mortality, with disease interactions increasing the severity of patients' colitis[1] Results from an international consensus project involving a multidisciplinary group of clinicians have been ...
plus
11.04.2016 – 09:16
Merck Healthcare Germany
Merck Makes Pioneering Technologies Gavi, Geri and Gems Available to Fertility Clinics
Darmstadt, Germany (ots/PRNewswire) - Not intended for U.S. based media - Merck obtains CE mark certification for consumables of Gavi(TM) and Geri(TM) as well as for the embryo culture media suite Gems(TM) - Geri(TM) now incorporating innovative software module Geri(TM) Connect + Assess, allowing fertility labs enhanced control and consistency in embryo assessment - ...
plus
08.04.2016 – 09:01
Debiopharm International SA
Debiopharm International SA to Present the Latest Findings on Debio 1450 at ECCMID
Lausanne, Switzerland (ots/PRNewswire) - Debiopharm will be present at ECCMID in Amsterdam to share new data supporting the clinical development of its first in class Staphylococcus-selective antibiotic Debio 1450 Debiopharm International SA (Debiopharm), part of Debiopharm Group(TM), a Swiss-based global biopharmaceutical company, today announced three communications ...
plus
07.04.2016 – 09:08
Vifor Pharma GmbH
Recent Survey Shows That 1 in 3 People Do Not Know Symptoms of Iron Deficiency Despite 1 in 10 Currently Suffering or Having Suffered From the Condition
London (ots/PRNewswire) - - Landmark European Iron Deficiency Survey highlights the lack of awareness of the condition, which currently impacts more people than both diabetes and chronic heart failure worldwide. - The survey findings published to coincide with World Health Day 2016, which this year will be dedicated ...
plus

07.04.2016 – 09:03
Sanofi Pasteur MSD GmbH
GARDASIL® 9: 2-dose Schedule Approved in Europe
Lyon, France (ots/PRNewswire) - The European Commission granted marketing authorization for a two-dose schedule in 9-14 year old girls and boys for GARDASIL®9, the 9-valent HPV vaccine Sanofi Pasteur MSD announced today that the European Commission has approved a 2-dose schedule for adolescent girls and boys aged 9 to 14 for GARDASIL®9, its 9-valent Human Papillomavirus (HPV) vaccine, for use in the 31 countries ...
plus
06.04.2016 – 09:01
Clearly
Global Campaign Launches to Help the World to See www.clearly.world
Hong Kong (ots/PRNewswire) - 'Clearly' Campaign Aims To Unlock The Next Revolutionary Approaches To Eye Care For The People Who Need It Most There are 2.5 billion people around the world suffering from poor vision and no means of improving it. A new global campaign - Clearly - launches today to bring together innovators, scientists, technology firms and big business, with investors, governments and NGOs to solve this ...
plus
04.04.2016 – 16:01
Novo Nordisk
Saxenda® demonstrated significant improvements in cardiometabolic risk factors over three years compared with placebo
Boston (ots/PRNewswire) - For non-US medical media only. For journalistic assessment and preparation before publication. Oral Presentation# OR36-1 Today, new data from the three-year part of the phase 3a SCALE(TM) (Satiety and Clinical Adiposity - Liraglutide Evidence) Obesity and Prediabetes trial were presented at ...
plus
02.04.2016 – 19:18
Novo Nordisk
Victoza® (liraglutide 1.8 mg) Provided Superior HbA1c Reductions in Adults with Type 2 Diabetes Compared to Continued Sitagliptin Treatment
Boston (ots/PRNewswire) - For non-US medical media only. For journalistic assessment and preparation before publication. Abstract #689-P Findings from a clinical trial comparing Victoza® (liraglutide 1.8 mg) and sitagliptin (100 mg), both in combination with metformin, demonstrated that switching from sitagliptin ...
plus
02.04.2016 – 17:46
Novo Nordisk
Semaglutide Demonstrated Superior Improvements In Glycaemic Control Vs Placebo In Adults With Type 2 Diabetes
Boston (ots/PRNewswire) - For non-US medical media only. For journalistic assessment and preparation before publication. Abstract #OR15-1 Findings from the first phase 3a clinical trial for semaglutide, an investigational glucagon-like peptide-1 (GLP-1) analogue, demonstrated that treatment with semaglutide ...
plus
30.03.2016 – 13:39
Janssen Sciences Ireland UC
Janssen to Unveil New Hepatitis B and C Data at The International Liver Congress(TM) 2016 of the European Association for the Study of the Liver (EASL)
Cork, Ireland (ots/PRNewswire) - Includes several late breaking and oral presentations from across R&D pipeline Highlights potential of R&D pipeline to deliver several new hepatitis B and C regimens Janssen Sciences Ireland UC and certain Janssen affiliates* today announced it will present thirteen abstracts ...
plus

30.03.2016 – 08:01
Mundipharma International
Mundipharma Files New flutiform® K-Haler® Device for Adolescents and Adults with Asthma
Cambridge, England (ots/PRNewswire) - Mundipharma announced today that they have submitted a file to the UK regulatory authority, the Medicines and Healthcare products Regulatory Agency (MHRA) seeking a licence for its new product flutiform® K-Haler®. The indication sought is for the treatment of asthma in adults and adolescents where the use of a combination product ...
plus
29.03.2016 – 13:20
Shire Pharmaceuticals Group Plc
Shire Wins Patent Trial Against Watson Concerning LIALDA®
Lexington, Massachusetts (ots/PRNewswire) - LIALDA Patent Upheld and Extends through June 8, 2020 Shire plc (LSE: SHP, NASDAQ: SHPG) and its subsidiary, Shire Development LLC, announced today that the United States District Court for Southern Florida has upheld its patent for LIALDA® (mesalamine) delayed release tablets for the induction of remission in adults with active, mild to moderate ulcerative colitis and for the ...
plus
24.03.2016 – 13:01
Daiichi Sankyo Europe GmbH
Daiichi Sankyo to Present Findings From New Subgroup Analyses of Once-Daily LIXIANA® (edoxaban) in NVAF and VTE at ACC's 65th Annual Scientific Session
Munich (ots/PRNewswire) - - Four abstracts highlight new subgroup analyses from the global phase 3 ENGAGE AF-TIMI 48 and Hokusai-VTE studies to be presented in oral and poster sessions Daiichi Sankyo Europe GmbH Group (hereafter, Daiichi Sankyo) today announced that data from three new subgroup analyses from the ...
plus
23.03.2016 – 12:46
Gairdner Foundation
2016 Canada Gairdner Awards Honour CRISPR-Cas Researchers and HIV/AIDS Leaders
Toronto (ots/PRNewswire) - The Gairdner Foundation is pleased to announce the winners of the 2016 Canada Gairdner Awards, recognizing some of the most significant medical discoveries from around the world. This year the awards center on two defining themes including the revolutionary Clustered regularly-interspaced short palindromic repeats (CRISPR) technique for gene ...
plus
22.03.2016 – 10:31
Nestlé Waters
On World Water Day, Nestlé Waters Expands its TOGETHER 4 WATER Events with Project WET and Reaffirms its Commitment to Water Stewardship
Paris (ots/PRNewswire) - Since 2010, World Water Day, held annually on March 22 by the United Nations, has been an opportunity for Nestlé Waters and the Project WET (Water Education for Teachers) Foundation to educate younger generations about the importance of freshwater. World Water Day 2016 marks the expansion ...
plus
21.03.2016 – 12:01
Oxitec
World Health Organization (WHO) Issues Positive Recommendation for Oxitec's Self-limiting Mosquito
Oxford (ots/PRNewswire) - The World Health Organization (WHO) has posted the conclusions and recommendations of the Vector Control Advisory Group (VCAG) meeting from March 14-15, 2016, regarding vector control tools for use in response to the recent Zika virus outbreak. After their review of several new tools with the potential to reduce vector populations, the VCAG ...
plus

Précédent35363738394041424344Suivant